Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 993

BillFederalSenateIn Committee
To prohibit certain uses of xylazine, and for other purposes.
About This Bill
Committee
Latest Action · January 11, 2024
Committee on Banking, Housing, and Urban Affairs. Hearings held.
Congress
118th (2023–2025)
Introduced
March 28, 2023
Cosponsors (30)
15D 15R
View PDF ↗

Summary

Highlight any text to annotate
Combating Illicit Xylazine Act This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq, is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.) Specifically, the bill establishes criminal penalties for manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, xylazine for illicit use (i.e., for use in humans) in accordance with the penalties for schedule III substances (up to 10 years imprisonment or, if death or serious bodily injury occurs, up to 15 years imprisonment, as well as criminal fines). In addition, the DEA must coordinate with the Food and Drug Administration to report on the prevalence of the illicit use of xylazine, including associated supply chains. The bill also declares the illicit use of xylazine as an emerging drug threat.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.